Here's a regular as you can get with very little heartburn over the years. GAIN. Had it for ages. Pays and pays.
that post was during my short lived "investment" phase lol, but i do ultimately have a goal of growing a little money in safer vehicles, so i'll take a look at it
Hey guys just a reminder that our largest holding in the GREEN GARDEN portFolio reports next week. WSC $34+ <----------------
<<<<THE SAVANT SAYS>>>> A New Independent GBA Review For You.- Let's Go! Nov 1. ) ) ) ) Idea #1- Porch Group. Porch Group initiated with a Buy at Loop Capital 07:29 PRCH Loop Capital analyst Mark Schappel initiated coverage of Porch Group with a Buy rating and $30 price target. The analyst is positive on the company's leverage to the "enormous and underserved" home services market that is on the cusp of a "technology awakening" as well as its unique vertical solutions and disruptive business model that allow the company to break away from small private home services vendors. Porch is poised to disrupt the age-old insurance industry, having found early access to homebuyers through home inspection and title processes, Schappel tells investors in a research note. Idea #2- Grid Dynamics Grid Dynamics initiated with a Buy at Citi 07:20 GDYN Citi analyst Ryan Potter initiated coverage of Grid Dynamics with a Buy rating and $35 price target. The company is "fully exposed to the positive and accelerating digital transformation trend with proven technology expertise and high quality engineering talent," Potter tells investors in a research note. The analyst sees 20%-plus revenue growth for multiple years and views Grid Dynamics's risk/reward as attractive. Ok good start those are two names you guys know well by now. I was looking at Grid all last week which makes it an especially Savant pick for the moment. Snap, Facebook, Twitter, YouTube lose $10B after iPhone privacy changes, FT says 06:06 AAPL, SNAP, FB, TWTR, GOOG, GOOGL Apple's (AAPL) iOS… Who do we not see there-- RBLX. They had their own problems this past weekend... But the thesis seems sound... RBLX not hurt as much by Apple... BUY RBLX on weakness. Organigram reports 7.7% national market share position in September 06:05 OGI Organigram believes that market share continues to be an important indication of success for a licensed producer as sell through to end consumers is a strong predictor of long-term sustainable revenue. The company continues its impressive market share growth trajectory in Canada, moving from a 3.9% market share position in January 2021 to a 7.7% national market share position in September 2021, securing the #4 position among Canadian LPs. Walmart, Sam's Club to launch eyewear collection created by Elton John 06:02 WMT Elton John Eyewear, a new line of stylish, accessible eyewear, is launching at Sam's Club on November 1, and at Walmart later this week. Fevertree Drinks upgraded to Buy from Hold at Deutsche Bank 04:39 FQVTF Deutsche Bank analyst Mitch Collett upgraded Fevertree Drinks to Buy from Hold with a 3,300 GBp price target. The target is based on a 50% probability of Fevertree matching U.K. penetration in its early-stage markets including the U.S. Ferrari is the favorite electric vehicle stock at Morgan Stanley (RACE) Morgan Stanley makes no secret that Ferrari(NYSE:RACE)is its favorite electric vehicle stock with the company set to show off its technical capability, compelling designs and expanding total addressable market. Analyst Adam Jonas: "We believe the current price assigns little to no value for RACE’s EV strategy. We assume Ferrari BEV sales begin in FY25 and ramp to more than 30% of Ferrari unit volume by 2030. If we assume 24x EBITDA on our FY2030 ICE derived earnings (roughly where stock is trading), discounted back to the present at an 8% WACC, we can justify ~98% of the company’s enterprise value. Backing out the ICE value from the company’s current share price suggests an EV business worth less than $1bn." Morgan Stanley assigns a price target of $265 to RACE vs. theaverage Wall Street PT of $220.36. Chubb price target raised to $225 from $198 at Credit Suisse 07:26 CB Avantor price target raised to $48 from $45 at Citi 07:23 AVTR Citi an STONEY SPECIAL OF THE DAY- Stocks You Don't know About---> GLOBAL CROSSING AIR Global Crossing Airlines inducts first A321 for cargo conversion 08:10 JETMF ON Semiconductor sees Q4 EPS 89c-$1.01, consensus 75c 08:05 ON Net 1 UEPS to acquire the Connect Group for $242M 08:03 UEPS Evelo Biosciences upgraded to Buy from Neutral at Chardan 08:02 EVLO Charda GUMMY OF THE DAY - EVLO MSG Sports price target raised to $220 from $190 at JPMorgan » 07:48 MSGS WE HERE! Morgan Stanley says bulls can keep running through Thanksgiving, but not much longer: At the Open Nov. 01, 2021 "Bottom line, the fundamental picture for stocks is deteriorating as the Fed starts to tighten monetary policy and earnings growth slows further into next year, turning outright negative for some companies," "Meanwhile, with strong seasonal trends and pressure to perform high at this time of year, many institutional investors we speak with are staying fully invested for these technical reasons. If our analysis is correct, we think that this bullish trend can continue into Thanksgiving, but not much longer."
***In at $146 it is a very boring stock that is always $144...... I dunno... I'm losing faith. I like that Magna. from Canada.
OUCH!!!!!!! Do you still own this? You never mentioned you closed it. I don't think it ever went above your purchase price. I haven't looked at in awhile, I knew it dropped huge, and now they just filed a 6-K with the SEC a few minutes ago. Laying off 35% of their staff to save cash. BYSI--------> $4.38 +++++++++++++++++++++++++++ http://archive.fast-edgar.com/20220111/AO2ZB22CZ222K2I2222F2W42GWMMZC22DW42/ On January 11, 2022, BeyondSpring Inc. (the “Company”) issued a press release announcing a reduction in force (RIF), as the Company re-focuses its resources on extending its cash runway and preserving long-term sustainability in light of the recent complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The Company will reduce its U.S. workforce by approximately 35% to preserve cash resources.